Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental drugs
Sodelglitazar
Другие языки:

    Sodelglitazar

    Подписчиков: 0, рейтинг: 0
    Sodelglitazar
    Sodelglitazar skeletal.svg
    Clinical data
    Pregnancy
    category
    • N/A
    ATC code
    • None
    Legal status
    Legal status
    • Investigational
    Identifiers
    • [4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    Formula C23H21F4NO3S2
    Molar mass 499.54 g·mol−1
    3D model (JSmol)
    • CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=C(C=C(C=C3)C(F)(F)F)F)C)OC(C)(C)C(=O)O
    • InChI=1S/C23H21F4NO3S2/c1-12-9-15(6-8-18(12)31-22(3,4)21(29)30)32-11-19-13(2)28-20(33-19)16-7-5-14(10-17(16)24)23(25,26)27/h5-10H,11H2,1-4H3,(H,29,30)
    • Key:ZUGQWAYOWCBWGM-UHFFFAOYSA-N

    Sodelglitazar, formerly known as GW 677954, is a thiazole PPARδ receptor agonist developed by GlaxoSmithKline. While it is primarily active at the PPARδ receptor, it is considered a pan agonist with activity at PPARα and PPARγ receptors.

    Safety

    Phase 2 studies were terminated prior to completion due to safety findings in rodent studies.

    See also


    Новое сообщение